IL1B and Sepsis: Administration of MCC950, a small-molecule inhibitor of NLRP3 inflammasome39, decreased the levels of IL-1β in serum and improved the survival rate of mice treated with LPS (Fig. 3e,f), suggesting that aberrant activation of NLRP3 inflammasome directly contributes to UVRAGFS-associated massive inflammation during sepsis.